LifeSci Partners

LifeSci Partners operates a dual-platform structure: the advisory business provides strategic communications, investor relations, and scientific consulting to biotech companies, while LifeSci Ventures invests directly in early-stage therapeutics developers. The advisory work generates deal flow and proprietary insight that informs investment decisions, creating a sourcing advantage over traditional venture funds that lack a sector-specialist infrastructure alongside their capital.

LifeSci Ventures focuses on early-stage biotech companies, primarily seed and Series A rounds. The firm seeks companies where its advisory platform — particularly scientific communications and investor relations — can materially improve the odds of successful clinical development and subsequent fundraising. The strategy favors situations where capital alone is insufficient, and operational advisory support becomes a meaningful differentiator.

Founder and CEO Andrew McDonald leads the firm's strategic direction and investment activities. The specific investment committee composition is not publicly detailed, but the firm's integrated advisory and venture model suggests that scientific-domain experts from the advisory side contribute to due diligence and investment evaluation alongside the venture team.

Public record indicates LifeSci Partners invests across oncology, rare disease, immunology, and genetic medicine. The firm's advisory business serves companies pursuing small-molecule drugs, biologics, and gene therapies, which broadly mirrors the venture arm's therapeutic interests. The firm does not publicly exclude any specific therapeutic areas but is focused exclusively on the life sciences sector.

LifeSci Partners is both. The firm was founded as a life sciences advisory and strategic communications platform, and later built a dedicated venture capital arm — LifeSci Ventures — to invest directly in the same ecosystem. This dual structure is central to the firm's identity and deal-sourcing model, distinguishing it from pure advisory firms and from traditional healthcare venture funds that lack in-house communications and IR capabilities.